Please use this identifier to cite or link to this item: https://ahro.austin.org.au/austinjspui/handle/1/26597
Title: Ambulatory Oxygen in Fibrotic Interstitial Lung Disease: A Pilot, Randomized, Triple-Blinded, Sham-Controlled Trial.
Austin Authors: Khor, Yet H ;Holland, Anne E ;Goh, Nicole S L ;Miller, Belinda R;Vlahos, Ross;Bozinovski, Steven;Lahham, Aroub;Glaspole, Ian;McDonald, Christine F 
Affiliation: School of Medicine, University of Melbourne, Melbourne, Victoria, Australia
Department of Respiratory Medicine, Alfred Health, Melbourne, Victoria, Australia
Department of Medicine, Monash University, Melbourne, Australia
School of Health and Biomedical Sciences, RMIT University, Bundoora, Victoria, Australia
Menzies Institute for Medical Research, University of Tasmania, Tasmania, Australia
Institute for Breathing and Sleep
Department of Physiotherapy, Alfred Health and Monash University, Melbourne, Australia
Respiratory and Sleep Medicine
Issue Date: Jul-2020
Date: 2020-02-28
Publication information: Chest 2020; 158(1): 234-244
Abstract: Despite a lack of evidence, ambulatory oxygen therapy is frequently prescribed for patients with interstitial lung disease (ILD) and exertional desaturation. Patients often prefer portable oxygen concentrators to oxygen cylinders. This study aimed to examine the feasibility of conducting a clinical trial of ambulatory oxygen delivered via portable concentrators in patients with ILD. Is it feasible to conduct a clinical trial of ambulatory oxygen delivered via portable concentrators in patients with ILD? In this randomized, triple-blinded, sham-controlled trial, 30 participants with ILD and isolated exertional desaturation to < 90% on 6-minute walk tests were randomized to 12-week ambulatory oxygen or air delivered via portable concentrators, with assessments performed at baseline and weeks 4, 12, and 18. Primary outcomes were trial feasibility and the change in 6-minute walk distance (6MWD) on room air at week 12. Study recruitment was completed within 18 months, with six withdrawals. Participant blinding was successful, with the Bang's Blinding Index being 0 (95% CI, -0.40 to 0.40) for the oxygen group and 0 (95% CI, -0.42 to 0.42) for the sham group. No significant difference in 6MWD was seen between groups at week 12 (mean difference of -34 m [95% CI, -105 to 36], P = .34). For secondary outcomes, compared with the sham group, the oxygen group had a significantly higher Leicester Cough Questionnaire psychological domain score, indicating better cough-related quality of life (mean difference of 0.9 [95% CI, 0.2 to 1.6], P = .01), but a shorter duration of moderate-to-vigorous activities (mean difference of -135 [95% CI, -267 to -3], P = .04) at week 12. Based on the results of this pilot study, a definitive randomized controlled trial with a longer intervention duration is warranted to clarify therapeutic impacts of ambulatory oxygen in patients with ILD. Australian New Zealand Clinical Trials Registry; No.: ACTRN12617000054314; URL: www.anzctr.org.au/.
URI: https://ahro.austin.org.au/austinjspui/handle/1/26597
DOI: 10.1016/j.chest.2020.01.049
Journal: Chest
PubMed URL: 32113924
Type: Journal Article
Subjects: exertional hypoxemia
idiopathic pulmonary fibrosis
interstitial lung disease
oxygen
pulmonary fibrosis
Appears in Collections:Journal articles

Show full item record

Page view(s)

54
checked on Oct 4, 2024

Google ScholarTM

Check


Items in AHRO are protected by copyright, with all rights reserved, unless otherwise indicated.